Literature DB >> 24888894

Early onset epileptic encephalopathy caused by de novo SCN8A mutations.

Chihiro Ohba1, Mitsuhiro Kato, Satoru Takahashi, Tally Lerman-Sagie, Dorit Lev, Hiroshi Terashima, Masaya Kubota, Hisashi Kawawaki, Mayumi Matsufuji, Yasuko Kojima, Akihiko Tateno, Hadassa Goldberg-Stern, Rachel Straussberg, Dafna Marom, Esther Leshinsky-Silver, Mitsuko Nakashima, Kiyomi Nishiyama, Yoshinori Tsurusaki, Noriko Miyake, Fumiaki Tanaka, Naomichi Matsumoto, Hirotomo Saitsu.   

Abstract

OBJECTIVE: De novo SCN8A mutations have been reported in patients with epileptic encephalopathy. Herein we report seven patients with de novo heterozygous SCN8A mutations, which were found in our comprehensive genetic analysis (target capture or whole-exome sequencing) for early onset epileptic encephalopathies (EOEEs).
METHODS: A total of 163 patients with EOEEs without mutations in known genes, including 6 with malignant migrating partial seizures in infancy (MMPSI), and 60 with unclassified EOEEs, were analyzed by target capture (28 samples) or whole-exome sequencing (135 samples).
RESULTS: We identified de novo SCN8A mutations in 7 patients: 6 of 60 unclassified EOEEs (10.0%), and one of 6 MMPSI cases (16.7%). The mutations were scattered through the entire gene: four mutations were located in linker regions, two in the fourth transmembrane segments, and one in the C-terminal domain. The type of the initial seizures was variable including generalized tonic-clonic, atypical absence, partial, apneic attack, febrile convulsion, and loss of tone and consciousness. Onset of seizures was during the neonatal period in two patients, and between 3 and 7 months of age in five patients. Brain magnetic resonance imaging (MRI) showed cerebellar and cerebral atrophy in one and six patients, respectively. All patients with SCN8A missense mutations showed initially uncontrollable seizures by any drugs, but eventually one was seizure-free and three were controlled at the last examination. All patients showed developmental delay or regression in infancy, resulting in severe intellectual disability. SIGNIFICANCE: Our data reveal that SCN8A mutations can cause variable phenotypes, most of which can be diagnosed as unclassified EOEEs, and rarely as MMPSI. Together with previous reports, our study further indicates that genetic testing of SCN8A should be considered in children with unclassified severe epilepsy. Wiley Periodicals, Inc.
© 2014 International League Against Epilepsy.

Entities:  

Keywords:  De novo mutation; Early onset epileptic encephalopathies; SCN8A

Mesh:

Substances:

Year:  2014        PMID: 24888894     DOI: 10.1111/epi.12668

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  44 in total

1.  Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers.

Authors:  Rikke S Møller; Katrine M Johannesen
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  The Genetic Landscape of Epilepsy of Infancy with Migrating Focal Seizures.

Authors:  Rosemary Burgess; Shuyu Wang; Amy McTague; Katja E Boysen; Xiaoling Yang; Qi Zeng; Kenneth A Myers; Anne Rochtus; Marina Trivisano; Deepak Gill; Lynette G Sadleir; Nicola Specchio; Renzo Guerrini; Carla Marini; Yue-Hua Zhang; Heather C Mefford; Manju A Kurian; Annapurna H Poduri; Ingrid E Scheffer
Journal:  Ann Neurol       Date:  2019-12       Impact factor: 10.422

3.  Gain-of-function FHF1 mutation causes early-onset epileptic encephalopathy with cerebellar atrophy.

Authors:  Aleksandra Siekierska; Mala Isrie; Yue Liu; Chloë Scheldeman; Niels Vanthillo; Lieven Lagae; Peter A M de Witte; Hilde Van Esch; Mitchell Goldfarb; Gunnar M Buyse
Journal:  Neurology       Date:  2016-05-04       Impact factor: 9.910

4.  SCN8A encephalopathy: Research progress and prospects.

Authors:  Miriam H Meisler; Guy Helman; Michael F Hammer; Brandy E Fureman; William D Gaillard; Alan L Goldin; Shinichi Hirose; Atsushi Ishii; Barbara L Kroner; Christoph Lossin; Heather C Mefford; Jack M Parent; Manoj Patel; John Schreiber; Randall Stewart; Vicky Whittemore; Karen Wilcox; Jacy L Wagnon; Phillip L Pearl; Adeline Vanderver; Ingrid E Scheffer
Journal:  Epilepsia       Date:  2016-06-08       Impact factor: 5.864

Review 5.  The genetics of the epilepsies.

Authors:  Christelle M El Achkar; Heather E Olson; Annapurna Poduri; Phillip L Pearl
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 6.  Epileptic encephalopathies: new genes and new pathways.

Authors:  Sahar Esmaeeli Nieh; Elliott H Sherr
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

7.  The phenotypic spectrum of SCN8A encephalopathy.

Authors:  Jan Larsen; Gemma L Carvill; Elena Gardella; Gerhard Kluger; Gudrun Schmiedel; Nina Barisic; Christel Depienne; Eva Brilstra; Yuan Mang; Jens Erik Klint Nielsen; Martin Kirkpatrick; David Goudie; Rebecca Goldman; Johanna A Jähn; Birgit Jepsen; Deepak Gill; Miriam Döcker; Saskia Biskup; Jacinta M McMahon; Bobby Koeleman; Mandy Harris; Kees Braun; Carolien G F de Kovel; Carla Marini; Nicola Specchio; Tania Djémié; Sarah Weckhuysen; Niels Tommerup; Monica Troncoso; Ledia Troncoso; Andrea Bevot; Markus Wolff; Helle Hjalgrim; Renzo Guerrini; Ingrid E Scheffer; Heather C Mefford; Rikke S Møller
Journal:  Neurology       Date:  2015-01-07       Impact factor: 9.910

Review 8.  Stiripentol in the Management of Epilepsy.

Authors:  Katherine C Nickels; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

9.  Mutations in epilepsy and intellectual disability genes in patients with features of Rett syndrome.

Authors:  Heather E Olson; Dimira Tambunan; Christopher LaCoursiere; Marti Goldenberg; Rebecca Pinsky; Emilie Martin; Eugenia Ho; Omar Khwaja; Walter E Kaufmann; Annapurna Poduri
Journal:  Am J Med Genet A       Date:  2015-04-25       Impact factor: 2.802

10.  Prominent role of forebrain excitatory neurons in SCN8A encephalopathy.

Authors:  Rosie K A Bunton-Stasyshyn; Jacy L Wagnon; Eric R Wengert; Bryan S Barker; Alexa Faulkner; Pravin K Wagley; Kritika Bhatia; Julie M Jones; Marissa R Maniaci; Jack M Parent; Howard P Goodkin; Manoj K Patel; Miriam H Meisler
Journal:  Brain       Date:  2019-02-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.